| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,800 |
6,003 |
$1.08M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,062 |
5,109 |
$1.00M |
| 71046 |
Radiologic examination, chest; 2 views |
4,383 |
3,398 |
$476K |
| 70450 |
Computed tomography, head or brain; without contrast material |
835 |
592 |
$382K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,891 |
9,319 |
$379K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,463 |
1,184 |
$368K |
| 71250 |
|
541 |
415 |
$368K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,429 |
1,043 |
$312K |
| 80053 |
Comprehensive metabolic panel |
10,738 |
9,105 |
$297K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,315 |
2,352 |
$244K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,732 |
3,127 |
$203K |
| 36415 |
Collection of venous blood by venipuncture |
27,528 |
13,740 |
$186K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,811 |
3,598 |
$165K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,656 |
2,498 |
$159K |
| 80061 |
Lipid panel |
2,902 |
2,747 |
$137K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,040 |
2,884 |
$130K |
| 82607 |
|
2,300 |
2,167 |
$119K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,355 |
1,057 |
$103K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,935 |
2,562 |
$95K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,900 |
1,728 |
$83K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,980 |
1,723 |
$78K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
2,494 |
2,362 |
$75K |
| 71045 |
Radiologic examination, chest; single view |
567 |
475 |
$64K |
| 83735 |
|
2,530 |
2,186 |
$61K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,634 |
2,118 |
$60K |
| 84484 |
|
2,371 |
1,607 |
$56K |
| 84439 |
|
1,469 |
1,400 |
$50K |
| 73630 |
|
297 |
272 |
$48K |
| 81001 |
|
2,403 |
2,069 |
$48K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,127 |
1,461 |
$47K |
| 84703 |
|
981 |
875 |
$47K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,484 |
2,041 |
$46K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
80 |
75 |
$41K |
| 80306 |
|
613 |
513 |
$39K |
| 82550 |
|
2,109 |
1,811 |
$34K |
| 73610 |
|
199 |
177 |
$33K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
283 |
226 |
$30K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
73 |
53 |
$29K |
| 82150 |
|
1,545 |
1,406 |
$28K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
431 |
375 |
$28K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
501 |
479 |
$27K |
| 83690 |
|
1,618 |
1,479 |
$26K |
| 82553 |
|
1,662 |
1,396 |
$26K |
| 82043 |
|
718 |
676 |
$24K |
| 82803 |
|
229 |
169 |
$24K |
| J7050 |
Infusion, normal saline solution, 250 cc |
2,083 |
1,642 |
$22K |
| 72100 |
|
208 |
146 |
$22K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
445 |
398 |
$21K |
| 73562 |
|
152 |
113 |
$21K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,048 |
923 |
$19K |
| 73130 |
|
106 |
91 |
$16K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
199 |
174 |
$15K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
132 |
121 |
$14K |
| 83540 |
|
323 |
311 |
$14K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
138 |
124 |
$13K |
| 82746 |
|
192 |
186 |
$10K |
| 85610 |
|
361 |
264 |
$9K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,055 |
1,829 |
$8K |
| 73030 |
|
56 |
38 |
$8K |
| 0011A |
|
126 |
122 |
$7K |
| 83550 |
|
82 |
78 |
$7K |
| 85027 |
|
502 |
479 |
$6K |
| 87081 |
|
1,385 |
1,305 |
$5K |
| 36600 |
|
160 |
139 |
$5K |
| 82728 |
|
93 |
89 |
$5K |
| 80074 |
|
40 |
38 |
$4K |
| 87070 |
|
43 |
40 |
$4K |
| 87807 |
|
70 |
64 |
$4K |
| 0012A |
|
74 |
74 |
$4K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,649 |
1,442 |
$4K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
45 |
42 |
$4K |
| 91322 |
|
17 |
13 |
$3K |
| 83880 |
|
46 |
37 |
$3K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
85 |
75 |
$3K |
| 85379 |
|
17 |
15 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
433 |
406 |
$2K |
| 87040 |
|
28 |
12 |
$2K |
| 81003 |
|
712 |
622 |
$2K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
76 |
50 |
$2K |
| 85652 |
|
88 |
85 |
$2K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
72 |
69 |
$815.05 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
29 |
15 |
$777.63 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
42 |
15 |
$559.10 |
| 86038 |
|
12 |
12 |
$510.70 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
13 |
12 |
$466.79 |
| 85730 |
|
32 |
28 |
$458.87 |
| 83605 |
|
30 |
26 |
$436.14 |
| 94664 |
|
14 |
13 |
$379.20 |
| 86803 |
|
27 |
13 |
$196.19 |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
20 |
12 |
$169.11 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
12 |
12 |
$30.39 |
| Q2037 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) |
25 |
12 |
$0.00 |